Background:
Poor adherence to topical therapy in psoriasis remains an issue; it is associated with poor clinical outcomes, reduced quality of life and increased costs. Treatment-related factors leading to poor adherence include lack of efficacy, excessive time applying medication and poor cosmetic characteristics (e.g. slow absorption, greasiness).
Objective:
To assess the topical treatment attributes that influence patient preference for fixed combination calcipotriol 50 μg/g (Cal) and betamethasone 0.5 mg/g as dipropionate (BD) foam vs. gel, as well as in comparison with the latest topical treatment (LTT) a patient received.
Methods:
PSO-INSIGHTFUL was a Phase IIIb, prospective, multicentre (Canada/Germany), open-label, randomized, two-arm crossover study in patients aged ≥18 years with mild-to-severe psoriasis (NCT02310646). Following a washout period of up to 4 weeks, patients were randomized 1 : 1 to once-daily Cal/BD foam for 1 week, followed by Cal/BD gel for 1 week, or vice versa. Patients completed six questionnaires evaluating patient preferences.
Results:
A total of 213 patients were randomized; 118 had received a topical treatment in the previous 3 months. Based on the Subject's Preference Assessment, 50% of patients preferred Cal/BD foam and 50% preferred Cal/BD gel. Based on the Topical Product Usability Questionnaire (TPUQ), overall mean scores were high for both Cal/BD foam and gel, and were often significantly in favour of both products compared with LTT. Greater differences between Cal/BD foam and gel vs. LTT occurred when the previous treatment was an ointment or cream. Cal/BD foam was generally preferred by younger patients (aged 18-39 years), whereas Cal/BD gel tended to be preferred by older patients (aged ≥40 years). Results from other questionnaires were aligned with the TPUQ.
Conclusions:
Patients with psoriasis have diverse needs and different preferences for topical treatment. This knowledge may help prescribers to choose the right formulation for the right patient, potentially leading to improved adherence and better treatment outcomes.
Citing Articles
Clinical Utility of Various Formulations of Calcipotriene and Betamethasone Dipropionate for the Treatment of Plaque Psoriasis in Patients Aged 12 Years or Older.
Kedra K, Reich A
Drug Des Devel Ther. 2024; 18:5827-5839.
PMID: 39670279
PMC: 11636291.
DOI: 10.2147/DDDT.S240867.
Exploring the Correlation between the PASI and DLQI Scores in Psoriasis Treatment with Topical Ointments Containing Mill. Extract.
Gavra D, Kosa D, Peto A, Jozsa L, Ujhelyi Z, Feher P
Pharmaceuticals (Basel). 2024; 17(8).
PMID: 39204197
PMC: 11359679.
DOI: 10.3390/ph17081092.
Calcipotriol/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety versus Topical Corticosteroids.
Gisondi P, Gracia-Cazana T, Kurzen H, Galvan J
J Clin Med. 2024; 13(15).
PMID: 39124750
PMC: 11313259.
DOI: 10.3390/jcm13154484.
Unveiling the potential of photodynamic therapy with nanocarriers as a compelling therapeutic approach for skin cancer treatment: current explorations and insights.
Mohanty S, Desai V, Jain R, Agrawal M, Dubey S, Singhvi G
RSC Adv. 2024; 14(30):21915-21937.
PMID: 38989245
PMC: 11234503.
DOI: 10.1039/d4ra02564d.
Matching-adjusted Indirect Comparison of Dermatology Life Quality Index 0/1 Response in Trials of Calcipotriol Plus Betamethasone Dipropionate Foam and Cream Formulations in Patients with Psoriasis.
Jalili A, Thoning H, Jablonski Bernasconi M, Papp K
Acta Derm Venereol. 2024; 104:adv12623.
PMID: 38327215
PMC: 10865104.
DOI: 10.2340/actadv.v104.12623.
Topical Treatment for the Management of Mild-to-Moderate Psoriasis: A Critical Appraisal of the Current Literature.
Fargnoli M, De Simone C, Gisondi P, Pellacani G, Calzavara-Pinton P
Dermatol Ther (Heidelb). 2023; 13(11):2527-2547.
PMID: 37737941
PMC: 10613180.
DOI: 10.1007/s13555-023-01024-9.
Topical proactive therapy in dermatology. A scoping review.
Makowska K, Nowaczyk J, Samochocki Z, Blicharz L, Rudnicka L
Postepy Dermatol Alergol. 2023; 40(4):510-517.
PMID: 37692271
PMC: 10485751.
DOI: 10.5114/ada.2023.129454.
Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application.
Praestegaard M, Steele F, Crutchley N
Dermatol Ther (Heidelb). 2022; 12(10):2217-2231.
PMID: 36050567
PMC: 9515249.
DOI: 10.1007/s13555-022-00794-y.
Pretreatment with an Aerosol Foam Containing Calcipotriene and Betamethasone Strongly Improves the Efficacy of Narrow-Band UVB Phototherapy.
Licata G, Arisi M, Venturini M, Rossi M, Tomasi C, Calzavara-Pinton I
Dermatol Ther (Heidelb). 2022; 12(9):2161-2171.
PMID: 36018478
PMC: 9464281.
DOI: 10.1007/s13555-022-00792-0.
Efficacy and Safety of Different Formulations of Calcipotriol/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment.
Rudnicka L, Olszewska M, Goldust M, Waskiel-Burnat A, Warszawik-Hendzel O, Dorozynski P
J Clin Med. 2021; 10(23).
PMID: 34884291
PMC: 8658256.
DOI: 10.3390/jcm10235589.
Preliminary Investigation of the Usability Characteristics Required for Wound Management Products by Semi-Structural Interview of Medical Staff.
Hirose K, Kawano Y, Shigeno N, Mizutani Y, Onishi H, Hanawa T
Pharmacy (Basel). 2020; 8(3).
PMID: 32842690
PMC: 7558683.
DOI: 10.3390/pharmacy8030152.
Medicated Foams and Film Forming Dosage Forms as Tools to Improve the Thermodynamic Activity of Drugs to be Administered Through the Skin.
Gennari C, Selmin F, Minghetti P, Cilurzo F
Curr Drug Deliv. 2019; 16(5):461-471.
PMID: 30657040
PMC: 6637090.
DOI: 10.2174/1567201816666190118124439.
Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature.
Pinter A, Thormann H, Angeletti F, Jalili A
Clin Cosmet Investig Dermatol. 2018; 11:451-459.
PMID: 30349342
PMC: 6183653.
DOI: 10.2147/CCID.S180698.
Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis.
Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J
Mol Pain. 2018; 14:1744806918762205.
PMID: 29448914
PMC: 5993069.
DOI: 10.1177/1744806918762205.